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ABSTRACT Mortality and symptom burden from chronic obstructive pulmonary disease (COPD) and
lung cancer are similar but there is thought to be an inequality in palliative care support (PCS) between
diseases. This nationally representative study assessed PCS for COPD patients within primary care in the
UK.
This was a cohort study using electronic healthcare records (2004–2015). Factors associated with
receiving PCS were assessed using logistic regression for the whole cohort and deceased patients.
There were 92365 eligible COPD patients, of which 26135 died. Only 7.8% of the whole cohort and
21.4% of deceased patients received PCS. Lung cancer had a strong association with PCS compared with
other patient characteristics, including Global Initiative for Chronic Obstructive Lung Disease stage and
Medical Research Council Dyspnoea score (whole cohort, lung cancer: OR 14.1, 95% CI 13.1–15; deceased
patients, lung cancer: OR 6.5, 95% CI 6–7). Only 16.7% of deceased COPD patients without lung cancer
received PCS compared with 56.5% of deceased patients with lung cancer. In patients that received PCS,
lung cancer co-diagnosis significantly increased the chances of receiving PCS before the last month of life
(1–6 versus ⩽1 month pre-death: risk ratio 1.4, 95% CI 1.3–1.7).
Provision of PCS for COPD patients in the UK is inadequate. Lung cancer, not COPD, was the
dominant driver for COPD patients to receive PCS.
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Introduction
Globally, chronic obstructive pulmonary disease (COPD) prevalence is on the rise and is the only disease
that continues to have an increasing age-adjusted mortality rate [1]. In the UK, 5.2% of all deaths are
secondary to COPD, which is approaching the proportion (6.2%) of deaths that are due to lung cancer [2,
3]. Patients with advanced COPD have a burden of disabling physical symptoms that are often
compounded by multiple comorbidities, psychological distress and social isolation. Currently, there is a
lack of palliative care support (PCS) for patients with end-stage COPD, despite evidence that it improves
their quality of life [4, 5]. The natural course of physical decline for patients with COPD can be variable,
but overall it is characterised by a long-term steady deterioration [6]. However, most healthcare resources
are dedicated towards management and prevention of acute events, with significantly less emphasis from
physicians and researchers on palliative and supportive care [7].
The 2010 National Institute for Health and Clinical Excellence (NICE) guidelines state that patients with
end-stage COPD should have access to the full range of services offered by palliative care teams [8]. These
include palliation for breathlessness and other symptoms, advance care planning, addressing emotional
and social needs, and end-of-life care. However, compared with patients with lung cancer who suffer from
a similar burden of disabling symptoms and psychological distress, small studies or studies using select
COPD cohorts have found over the past decade that COPD patients often have limited access to palliative
care services [9–13], even when compared with patients with other chronic terminal diseases [14]. It is
likely that a major reason for this is the difficulty in predicting when to initiate PCS; current
recommendations are to deliver PCS during the last year of life, but prognosticating the life expectancy of
individuals with COPD has proven to be extremely difficult [1, 15, 16]. Consequentially, there is no
commonly accepted definition of “end-stage COPD”. In addition, it is well recognised that communication
between COPD patients with advanced disease and physicians remains poor regarding disease prognosis
and end-of-life planning, which is likely to be related to a lack of training and guidance [17, 18].
Previous studies have investigated the planning of PCS from acute UK hospital trusts; unfortunately, these
have consistently found poor access for COPD patients to palliative care services, alongside limited
provision of patient information [19, 20]. This is the first nationally representative study to describe the
uptake of PCS in COPD patients, the characteristics that are associated with receiving PCS and how this
has changed over the past decade.
Methods
Data sources
The UK Clinical Practice Research Datalink (CPRD) includes 674 general practitioner (GP) practices and
has current coverage of over 11.3 million patients, and represents the UK’s population with respect of age,
sex, body mass index (BMI) and ethnicity [21]. Approximately 60% of CPRD practices have patient-level
linkage to Hospital Episode Statistics (HES) data and Office of National Statistics (ONS) mortality data.
Study design and population
We conducted an open cohort study of COPD patients that contribute towards routinely collected CPRD–
HES–ONS linked electronic healthcare records (figure 1). Patients had to have a COPD diagnosis as
determined using a previous validated algorithm [22]. Patients entered the study 1 year after their latest
COPD diagnosis date, the date the practice began recording research quality data, their continuous
CPRD-GP registration date or study start date (December 31, 2004). Patients were censored at date of
death, the end of the study period (March 31, 2015), the GP practice last data collection date or the date
of transfer out of a CPRD-linked practice.
Outcome and variables
The primary outcome was documentation of PCS, as recorded in the patients’ electronic healthcare
records using relevant Read Codes (the clinical terminology system used by CPRD); two-thirds of codes
were for “terminal care”, “palliative care”, “on gold standards palliative care framework” or “palliative care
plan review”; other commonly used codes included “palliative care treatment”, “palliative care specialist” or
“seen by palliative care physician” (supplementary table S1). A history of smoking (current or ex-smoker),
myocardial infarction, lung cancer, heart failure, stroke, anxiety and depression was identified using
appropriate Read Codes. BMI (kg·m−2) was categorised as underweight (<19 kg·m−2), normal
(19–25 kg·m−2), overweight (25–30 kg·m−2) or obese (⩾30 kg·m−2). Exacerbations were identified using a
validated algorithm [23]; the baseline year was defined as the year before study entry. A moderate
exacerbation was defined as having been treated within the GP practice, while a severe exacerbation was
defined as requiring hospitalisation; exacerbations recorded within 14 days of the index exacerbation were
considered as the same event. COPD severity was classified using Global Initiative for Chronic Obstructive
Lung Disease (GOLD) staging classification and the Medical Research Council (MRC) Dyspnoea scale [24, 25].
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Death was defined as death from any cause in the analysis; however, in a sensitivity analysis, we
investigated a subgroup of patients for whom it was highly likely COPD led directly to the cause of death
based upon ONS data.
Statistical analysis
Logistic regression was used to calculate the association between patient characteristics and PCS, for the
whole cohort and for the deceased patients. Multivariate logistic regression was conducted using the
following variables: sex, age at study entry, history of myocardial infarction, stroke, lung cancer, anxiety,
depression, heart failure, BMI, GOLD stage, MRC Dyspnoea score, smoking status and number of
exacerbations in the baseline year. These demographic and clinical variables, taking into account disease
severity and comorbidity, were selected as known or suspected risk factors for receiving PCS [11–13].
Where data was <25% missing, a complete case analysis was undertaken; for variables with >25% missing,
the variable was excluded from the multivariate regression model (GOLD stage in the whole cohort and
deceased subpopulation, and MRC Dyspnoea score in the deceased subpopulation) and a sensitivity
analysis was then carried out to include that variable in the model. Multinomial regression was applied to
estimate the relative effect of a coexisting lung cancer diagnosis on the timing of the PCS in relation
to time of death. Two time periods, i.e. “early period” (6–12 months before death) and “medium period”
(1–6 months before death), were compared to the “late period” (⩽1 month before death). Statistical
analysis was conducted using Stata version 14.1 (StataCorp, College Station, TX, USA).
Ethics
The protocol for this research was approved by the Independent Scientific Advisory Committee (ISAC) for
Medicines and Healthcare Products Regulatory Agency Database Research (protocol 17_083); the
approved protocol was made available during peer review. Generic ethical approval for observational
COPD patients
CPRD–HES–ONS linked data
during study time period
n=117 435
Excluded:
<1 year of research
quality data
n=25 070
Eligible patients
n=92 365
Deceased patients
n=26 135
Deceased patients that 
received PCS
n=5595
FIGURE 1 Flowchart of patient inclusion in the study. COPD: chronic obstructive pulmonary disease; CPRD:
Clinical Practice Research Datalink; HES: Hospital Episode Statistics; ONS: Office of National Statistics; PCS:
palliative care support.
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research using the CPRD with approval from the ISAC was granted by a Health Research Authority
Research Ethics Committee (East Midlands – Derby; 05/MRE04/87).
Results
Characteristics of the whole cohort
There were 92365 eligible COPD patients in the cohort (figure 1). At study entry, mean age was
67.8 years, 49801 (53.9%) were male, 18962 (20.6%) had cardiovascular disease (myocardial infarction,
stroke or heart failure), 31260 (33.8%) had anxiety or depression, 30656 (34.1%) had a normal BMI,
46900 (52.3%) were current smokers, 19841 (35.2%) had GOLD stage ⩾3, 18295 (25.5%) had MRC
Dyspnoea score ⩾4, 46898 (50.8%) had no exacerbations in their baseline year and 26135 (28.3%) died
during study follow-up (table 1).
During follow-up (median (interquartile range (IQR)) 4.2 (1.9–7.2) years), only 7198 (7.8%) received PCS
through primary care. 4138 (4.5%) of the whole cohort were diagnosed with lung cancer by the end of
follow-up. In patients without a co-diagnosis of lung cancer, only 5.8% (5127 out of 88227) received PCS;
in contrast, in the subgroup of patients with COPD and lung cancer, 50% (2071 out of 4138) received
PCS.
Characteristics of the deceased patients
26135 patients died during the cohort follow-up. Compared with the whole cohort, deceased patients had
a slightly shorter follow-up time (median (IQR) 3.3 (1.5–5.6) years), were slightly older (mean age
74 years), but had a similar percentage of males (table 1). The proportion of patients with a history of
myocardial infarction, stroke, heart failure or lung cancer was higher in deceased COPD patients than the
cohort as a whole; anxiety and depression were of similar proportions. There was a higher proportion of
deceased COPD patients when compared with the whole cohort, who were underweight, ex-smokers, had
a higher GOLD stage, higher MRC Dyspnoea scores and more exacerbations in the baseline year (table 1).
During follow-up (median (IQR) 3.7 (1.5–5.6) years), only 4655 (22.5%) received or accessed PCS through
primary care. In patients without a co-diagnosis of lung cancer, only 16.7% (3831 out of 23014) received
PCS; in contrast, in the subgroup of patients with COPD and lung cancer, 56.5% (1764 out of 3121)
received PCS. In the sensitivity analysis, including only patients known to have died from their COPD,
there were 15745 patients, only 15.4% (1641) of whom had received PCS.
Longitudinal changes in the proportion of patients receiving PCS from 2005 to 2014
From 2005 to 2014, there was a steady rise in the proportion of patients who received PCS (figure 2). In
2005, 0.5% (216 out of the 39685 patients in the cohort in 2005) had received support; by 2014, 2.0% (907
out of the 44493 patients in the cohort in 2014) had received PCS. The proportion of deceased COPD
patients that received PCS followed a similar pattern, overall increasing from 1.2% in 2005 to 16.5% in
2014 (figure 2). The rate of increase over the years appeared to be the same for COPD patients with or
without lung cancer (supplementary figure S1).
Association between PCS and patient characteristics
In the whole COPD cohort, age ⩾75 years, being female, cardiovascular comorbidities (myocardial
infarction, stroke or heart failure), anxiety, underweight BMI, MRC Dyspnoea score ⩾2 and a history of
four or more moderate exacerbations or one or more severe exacerbation in the baseline year were
significantly associated with an increased odds of receiving PCS after adjusting for all other characteristics
(table 2); being overweight or obese was significantly associated with a reduced odds of receiving PCS
(table 2). Lung cancer had the strongest association with receiving PCS, even after adjusting for all other
characteristics (adjusted OR 14.7, 95% CI 13.5–16).
In the deceased patients, age ⩽65 years, anxiety and not being obese were significantly associated with an
increased odds of receiving PCS after adjusting for all other characteristics (table 2). The reduced
association of PCS with heart failure may be related to residual confounding from age as it tended towards
unity after the multivariate analysis. Lung cancer had the strongest association with receiving PCS, even
after adjusting for all other characteristics (adjusted OR 6.5, 95% CI 5.5–6.8).
The sensitivity analysis that included GOLD stage in both multivariate models showed little difference in
the odds ratios (whole cohort, lung cancer: adjusted OR 14.4, 95% CI 13–15.9; p<0.0001; deceased
patients, lung cancer: adjusted OR 6.1, 95% CI 5.4–6.9; p<0.0001). The sensitivity analysis that included
the MRC Dyspnoea score in the deceased patients multivariate model showed little difference in the odds
ratios (deceased patients, lung cancer: adjusted OR 6.1, 95% CI 5.5–6.7; p<0.0001).
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Timing of PCS in respect to the patient’s death
Only 21.4% of deceased COPD patients received PCS (5595 out of 26135), of whom 31.5% had a
co-diagnosis of lung cancer (1764 out of 5595). Of those that had received PCS, 48.4% received it only
within 6 months of their death (of whom 29.1% had lung cancer) (figure 3).
Using multinomial regression, it can be seen that patients with COPD and lung cancer were more likely to
receive PCS earlier in their last 12 months of life (⩽11 months pre-death) than patients who only had a
COPD diagnosis (figure 4). There was a 40% increased chance of receiving support within 1–6 months
pre-death and 30% increased chance of receiving PCS within 6–12 months pre-death, compared with
receiving palliative care at a late time period (⩽1 month pre-death), for patients with both COPD and lung
cancer compared with not having lung cancer (middle versus late for “COPD+lung cancer” versus “COPD
alone”: risk ratio 1.4, 95% CI 1.3–1.7; p<0.0001; early versus late for “COPD+lung cancer” versus
“COPD alone”: risk ratio 1.3, 95% CI 1.1–1.6; p<0.01).
Discussion
From a large primary care cohort of 92365 COPD patients, only 7.8% of the whole cohort and 21.4% of
deceased patients received PCS during the study follow-up. However, just under a third of these patients
TABLE 1 Demographic and clinical characteristics of the whole chronic obstructive pulmonary disease (COPD) cohort and the
deceased COPD patients from 2005 to 2014
Whole cohort Deceased patients
Whole cohort Received PCS No PCS Deceased patients Received PCS No PCS
Total (% of total) n=92365 (100) n=7198 (7.8) n=85167 (92.2) n=26135 (100) n=5595 (21.4) n=20540 (78.6)
Follow-up years 4.2 (1.9–7.2) 4.3 (2.2–7.0) 4.1 (1.9–7.3) 3.3 (1.5–5.6) 3.9 (2–6.3) 3.1 (1.4–5.3)
Age years 67.8±11.4 71.8±9.7 67.5±11.6 74±9.6 72.3±9.3 74.5±9.5
Age category years
⩽65 35994 (39) 1703 (23.7) 34291 (40.3) 4628 (17.7) 3408 (16.6) 1220 (21.8)
65–75 29424 (31.9) 2624 (36.5) 26800 (31.5) 8339 (31.9) 6296 (30.7) 2043 (36.5)
⩾75 26947 (29.2) 2871 (39.9) 24076 (28.3) 13168 (50.4) 10836 (52.8) 2332 (41.7)
Male 49801 (53.9) 4134 (57.4) 45667 (53.6) 15215 (58.2) 3256 (58.2) 11959 (58.2)
Myocardial infarction 6232 (7.4) 726 (10.1) 6309 (7.4) 3004 (11.5) 576 (10.3) 2428 (11.8)
Stroke 5526 (6.1) 573 (8) 5062 (5.9) 2390 (9.1) 451 (8.1) 1939 (9.4)
Heart failure 9673 (10.6) 1140 (15.8) 8747 (10.3) 5335 (20.4) 903 (16.1) 4432 (21.6)
Lung cancer 4138 (4.5) 2071 (28.8) 2380 (2.8) 3121 (11.9) 1764 (31.5) 1357 (6.6)
Anxiety 19990 (21.9) 1765 (24.5) 18536 (21.8) 5425 (20.8) 1356 (24.2) 4069 (19.8)
Depression 21836 (23.9) 1693 (23.5) 20459 (24.0) 5375 (20.6) 1268 (22.7) 4107 (20)
BMI kg·m−2 n=86789 n=6486 n=89789 n=24686 n=5382 n=19304
<19 (underweight) 8144 (9.1) 1060 (15.3) 7084 (8.6) 4075 (16.5) 843 (15.7) 3232 (16.7)
19–25 (normal) 30656 (34.1) 2780 (40) 27876 (33.7) 9842 (39.9) 2207 (41) 7635 (39.6)
25–30 (overweight) 27738 (30.9) 1854 (26.7) 25884 (31.3) 6272 (25.4) 1417 (26.3) 4855 (25.2)
⩾30 (obese) 23251 (25.9) 1253 (18) 21998 (26.7) 4497 (18.2) 915 (17) 3582 (18.6)
Smoking status n=89789 n=6726 n=84392 n=24686 n=5382 n=19304
Current smoker 46900 (52.3) 3440 (49.5) 43460 (52.5) 11744 (47.6) 2646 (49.2) 9098 (47.1)
Ex-smoker 42889 (47.8) 3507 (50.5) 39382 (47.5) 12942 (52.4) 2736 (50.8) 10206 (52.9)
GOLD stage n=56159 n=5017 n=59362 n=16118 n=3614 n=12504
1 12996 (23.1) 917 (19.7) 12049 (23.4) 3411 (21.2) 723 (20) 2688 (21.5)
2 23352 (41.6) 1651 (35.5) 21701 (42.1) 4989 (31) 1249 (34.6) 3740 (29.9)
3 15259 (27.2) 1442 (31) 13817 (26.8) 5360 (33.3) 1132 (31.3) 4228 (33.8)
4 4582 (8.2) 643 (13.8) 3939 (7.7) 2358 (14.6) 510 (14.1) 1848 (14.8)
MRC Dyspnoea score n=71985 n=4656 n=66177 n=15104 n=3668 n=11436
1 11168 (15.5) 393 (7.7) 10775 (16.1) 1156 (7.7) 296 (8.1) 860 (7.5)
2 23856 (33.1) 1099 (21.6) 22757 (34) 3097 (20.5) 774 (21.1) 2323 (20.3)
3 18666 (25.9) 1233 (24.2) 17433 (26) 3899 (25.8) 877 (23.9) 3022 (26.4)
4 13644 (19) 1421 (27.9) 12223 (18.3) 4431 (29.3) 1011 (27.6) 3420 (29.9)
5 4651 (6.5) 943 (18.5) 3708 (5.5) 2521 (16.7) 710 (19.4) 1811 (15.8)
Exacerbations in baseline year n=92365 n=6726 n=91201 n=26135 n=5595 n=20540
0 46898 (50.8) 3227 (44.8) 43671 (51.3) 11762 (45) 2516 (45) 9246 (45)
⩽2 (moderate) 27991 (30.3) 2178 (30.3) 25813 (30.3) 7690 (29.4) 1695 (30.3) 5995 (29.9)
⩾3 moderate/⩾1 severe 17476 (18.9) 1793 (24.9) 15683 (18.4) 6683 (25.6) 1384 (24.7) 5299 (25.8)
Data are presented as median (interquartile range), mean±SD or n (%), unless otherwise stated. PCS: palliative care support; BMI: body mass
index; GOLD: Global Initiative for Obstructive Lung Disease; MRC: Medical Research Council.
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also had lung cancer; it is highly probable that many patients were receiving PCS in respect of their cancer
diagnosis rather than their airways disease. Indeed, only 6% of COPD patients without lung cancer were
provided with PCS compared with 50% of the lung cancer patients in the whole cohort. A co-diagnosis of
lung cancer had the strongest association with PCS compared with any of the other measured patient
characteristics, in both the whole cohort (15 times increased odds of receiving PCS) and in only the
deceased patients (6 times increased odds of receiving PCS). Therefore, the largest influence on PCS for
COPD patients was not related to the advancement of their airways disease but to having lung cancer.
However, it is encouraging that the proportion of COPD patients who received PCS steadily increased
between 2005 and 2014, in particular for the deceased COPD patients, both with and without lung cancer.
The rise was steepest from 2009 onwards, which could be related to the introduction of the national End
of Life Care Strategy, a programme developed to specifically reach patients with nonmalignant life-limiting
diseases, and is in keeping with data showing a reduction in undesirable hospital deaths in COPD patients
over the same time period [26].
Palliative care is not just synonymous with end-of-life care, but also centres on symptom management,
improving a patient’s quality of life, and psychological support for the patient and their family. Indeed,
modern palliative care approaches are more needs based rather than prognosis based, appropriate for
COPD patient’s whose life expectancy is difficult to predict [4]. Two other factors, i.e. anxiety and MRC
Dyspnoea score, indicative of requiring support for psychological and symptom management, respectively,
were also significantly associated with PCS in the whole cohort, suggesting PCS was considered for
symptom control, but to a far lesser degree than a coexisting diagnosis of lung cancer. Having a high BMI
was associated with a reduced chance of receiving PCS; this may reflect a lack of an understanding/
willingness to consider PCS in obese COPD patients who may suffer with a relatively increased sensation of
breathlessness [27]. Interestingly, older age (⩾75 years) was associated with an increased odds of receiving
PCS in the whole cohort, but younger age was significantly associated with an increased odds of receiving
support in the deceased patients. The deceased patients were a frailer cohort with more comorbidities and
more severe clinical features; it could be that in this setting a younger patient is more likely to be considered
for PCS than an older patient and it is noteworthy that a similar ageist phenomenon has been recognised in
studies addressing referral of general cancer patients to palliative care services [28].
It is also imperative that provision of PCS occurs in a timely manner, not just a few weeks before death
[29]. Sadly, this study found that a third of COPD patients only received PCS in the last month of their
life. In addition, there was again an inequality between patients with or without a lung cancer diagnosis.
Those with lung cancer had an increased chance of receiving PCS earlier in the year before death, whereas
patients without lung cancer were much more likely to receive PCS during their final month of life.
The inequality between PCS for COPD patients and lung cancer patients has previously also been noted in
other countries [17], yet the two diseases are comparable in their manifestation and severity of symptoms.
Moreover, several studies have shown that end-stage COPD patients have at least as many, if not more,
physical and psychological needs as patients with end-stage lung cancer [30]. It appears that often it was
only the terminal care element of PCS that was provided for COPD patients without lung cancer.
However, it has been shown previously that even this aspect of PCS is relatively lacking as COPD patients
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are more likely to die in hospital than lung cancer patients, which is not in keeping with the general
preference to die at home [31, 32].
It has been nearly two decades since a small UK study suggested that PCS was lacking in COPD patients
compared with those with lung cancer [13]. Despite an increased recognition during this time that patients
TABLE 2 Association between lung cancer and other patient characteristics and receiving
palliative care support for the whole chronic obstructive pulmonary disease (COPD) cohort and
the deceased COPD patients
Whole cohort Deceased patients
Crude OR
(95% CI)
Adjusted OR#
(95% CI)
Crude OR
(95% CI)
Adjusted OR#
(95% CI)
Lung cancer
No 1 (reference) 1 (reference)
Yes 14 (13.0–15.0)*** 14.7 (13.5–16.0)*** 6.5 (6–7)*** 6.1 (5.6–6.6)***
Age years
⩽65 1 (reference) 1 (reference)
65–75 2.0 (1.9–2.1)*** 1.6 (1.5–1.7) 0.9 (0.8–1)* 0.9 (0.9–1.1)
⩾75 2.4 (2.3–2.6)*** 1.9 (1.8–2.1)*** 0.6 (0.6–0.7)*** 0.7 (0.7–0.8)***
Sex
Female 1 (reference) 1 (reference)
Male 0.9 (0.8–0.9)*** 0.8 (0.8–0.9)*** 1.0 (0.9–1.1) 1.0 (0.9–1.1)
Myocardial infarction
No 1 (reference) 1 (reference)
Yes 1.4 (1.3–1.5)*** 1.2 (1.0–1.3)** 0.9 (0.8–0.9)** 0.9 (0.8–1.0)
Stroke
No 1 (reference) 1 (reference)
Yes 1.4 (1.3–1.5)*** 1.1 (1.0–1.3)* 0.8 (0.8–0.9)** 1 (0.8–1.1)
Heart failure
No 1 (reference) 1 (reference)
Yes 1.6 (1.5–1.8)*** 1.5 (1.3–1.6)*** 0.7 (0.7–0.8)*** 0.9 (0.8–0.9)**
Anxiety
No 1 (reference) 1 (reference)
Yes 1.2 (1.1–1.2)*** 1.3 (1.2–1.4)*** 1.3 (1.2–1.4)*** 1.2 (1.1–1.3)***
Depression
No 1 (reference) 1 (reference)
Yes 1.0 (0.9–1.0)*** 1.0 (0.9–1.1) 1.2 (1.1–1.3)*** 1.1 (1–1.2)
BMI
<19 (underweight) 1 (reference) 1 (reference)
19–25 (normal) 1.5 (1.4–1.6)*** 1.4 (1.3–1.6)*** 0.9 (0.8–1)* 0.9 (0.8–1)
25–30 (overweight) 0.7 (0.7–0.8)*** 0.7 (0.7–0.8)*** 1 (0.9–1.1) 1.0 (0.9–1.1)
⩾30 (obese) 0.6 (0.5–0.6)*** 0.6 (0.6–0.7)*** 0.9 (0.8–1.0)** 0.9 (0.8–1.0)**
Smoking
Ex-smoker 1 (reference) 1 (reference)
Current smoker 0.9 (0.8–0.9)*** 1 (0.9–1.1) 1.1 (1.0–1.2)** 1.0 (0.9–1.0)
GOLD stage
1 1 (reference) 1 (reference)
2 1.0 (0.9–1.1) 1.2 (1.1–1.4)***
3 1.4 (1.3–1.5)*** 1.0 (0.9–1.1)
4 2.1 (1.9–2.4)*** 1.0 (0.9–1.2)
MRC Dyspnoea score
1 1 (reference) 1 (reference)
2 1.3 (1.2–1.5)*** 1.2 (1.1–1.4)** 1 (0.8–1.1)
3 1.9 (1.7–2.2)*** 1.6 (1.4–1.8)*** 0.8 (0.7–1)*
4 3.2 (2.8–3.6)*** 2.4 (2.1–2.7)*** 0.9 (0.7–1)*
5 7.0 (6.2–7.9)*** 5.1 (4.5–5.8)** 1.1 (1–1.3)
Exacerbations
None 1 (reference) 1 (reference)
⩽2 (moderate) 1.1 (1.1–1.2)*** 1.0 (0.9–1.1) 1.0 (1–1.1) 1.0 (1–1.1)
⩾3 moderate/⩾1 severe 1.6 (1.5–1.6)*** 1.2 (1.1–1.3)*** 1.0 (0.9–1) 1.0 (1–1.1)
BMI: body mass index; GOLD: Global Initiative for Obstructive Lung Disease; MRC: Medical Research
Council. #: adjusted for all other characteristics in the table. *: p<0.05; **: p<0.01; ***: p<0.0001.
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with COPD would benefit from a palliative care approach, including implementation of NICE guidelines
and the national End of Life Care Programme and Strategy, our data have shown that there has been only
a limited increase in PCS uptake. This lack of deliverance from within primary care, including absence of
referral to specialist services, has been proposed to be multifactorial and related to difficulties in predicting
prognosis, inadequate expertise to engage in palliative care discussions, physician concern in using opioids
in chronic respiratory disease, fear of diminishing patients’ hopes and bias against patients with
smoking-related lung diseases [27]. Additional strategies are therefore required to help improve access to
PCS, including defining and sharing good models of care between the respiratory and palliative care
communities, enhanced training in identifying patients who will benefit, communication skills and
symptom management, as well as increasing the availability of evidence-based pharmacological and
nonpharmacological intervention [4, 33].
Study limitations
Recording of palliative care provision in primary care is one of the NICE Quality and Outcomes
Framework indicators and therefore, fortuitously, this incentive payment programme ensures high
recording of PCS. However, it is possible some instances of PCS were not recorded, such as a prescription
of opioids/benzodiazepines to palliate breathlessness, but it is likely most GPs would have documented the
reason for such prescriptions, especially given they are incentivised to use Quality and Outcomes
Framework Read Codes. In this study we only addressed PCS from within primary care, including referrals
to specialist services, but not including PCS provided during hospital admissions. Therefore, this study
may have excluded some patients who received PCS only through secondary care within the last couple of
weeks of their life and were not seen back in primary care after hospital/hospice discharge.
It is very difficult to identify which patients have “end-stage” COPD; therefore, as a proxy, we carried out
much of our analysis only on patients who had died. It is possible that we included some patients who did
not have end-stage COPD as they may have died from unrelated causes. However, using ONS data we also
identified a subgroup of patients whose deaths were highly likely to have been related to their COPD and
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FIGURE 3 Cumulative proportion of deceased chronic obstructive pulmonary disease (COPD) patients that first
received palliative care support (PCS) in relation to the time of their death and the proportion of those that
had a lung cancer co-diagnosis.
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FIGURE 4 Patients with a dual diagnosis, i.e. chronic obstructive pulmonary disease (COPD) and lung cancer,
were more likely to receive palliative care support (PCS) earlier before their death than patients with COPD
alone. RR: risk ratio (“COPD+lung cancer” versus “COPD”). Includes only deceased COPD patients that
received PCS within 12 months of their death.
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in that analysis the proportion of patients that received PCS in this subgroup was even lower than for the
total deceased population.
There was missing data for the MRC Dyspnoea score and, as we carried out a complete case analysis for
the whole cohort, it is possible there was some selection bias as these patients may have had more severe
disease (fewer patients had missing MRC Dyspnoea scores in GOLD stage 4 than stages 1–3); however,
this should not have affected the findings except to pull the estimate further from unity. Lastly, it is
possible that there were other factors (e.g. social and cultural preferences) which were not included in our
analysis that could have affected our findings; however, due to the strength of the association with lung
cancer that relationship is unlikely to have changed considerably.
Conclusions
This is the first nationally representative study to investigate the provision of PCS for COPD patients. We
have shown that the majority of COPD patients within primary care were not provided PCS in their last
year of life; when PCS was provided, it appeared to be related to their co-diagnosis of lung cancer rather
than their airways disease, including their disease severity (GOLD score and exacerbation frequency) or
their perceived respiratory disability (MRC Dyspnoea score). Furthermore, PCS was frequently only given
within the last few weeks of life, whereas patients with a lung cancer co-diagnosis were far more likely to
receive PCS in a more timely manner.
Many COPD patients suffer from symptom-related distress even when medical treatment has been
optimised. The low proportion of patients receiving PCS, not immediately before death, suggests it is an
especially poorly provided service with regard to its capacity to reduce symptom burden, improve quality
of life and reduce psychological distress. This study advocates an urgent need to improve all aspects of
PCS, not just terminal care, for COPD patients within the UK.
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